SURVEY: Understanding Clinicians’ perceptions of a Decision Support tool for Lung Cancer Treatment

Dear BOPA member,

Tarini Deleep and Dr Pinkie Chambers from University College London are developing a risk prediction model to help identify patients with incurable Non Small Cell Lung Cancer, who are at risk of serious adverse events (AE) related to their first-line systemic anti-cancer treatment (SACT). This is important because 38% of these patients treated with SACT will encounter an acute hospital visit due to an AE in their last year of life. The proposed risk score leverages real-world data to estimate the likelihood of hospitalisations caused by AEs. By providing a clearer understanding of treatment risks, this tool aims to improve communication between clinicians and patients about potential AE, ultimately supporting better SACT decision-making through individualised assessments of serious AE risks for patients with incurable lung cancer.

However, it is not yet understood how prescribers would use this risk model in practice. The work aims to understand how this risk score can impact a clinician’s treatment recommendations. In order to achieve this, an online survey has been designed that aims to understand clinician’s perceptions of a decision support tools for Lung Cancer treatment.

Please find the link to this survey here: https://qualtrics.ucl.ac.uk/jfe/form/SV_7339WZAz0rwQk6O

Latest News

By Mohammed Patel on 11th November 2026

UK BMT Pharmacists Group Educational Meeting – Friday 13th November 2026. Time:14:00 to 16:00

The next UK BMT Pharmacists Group Educational Meeting is on Friday 13th November, 2pm–4pm. The sessions include: Maintenance Therapy for AML After Allogeneic BMT with Dr Mili Shah, Consultant Haematologist,…

Read article
By UK SACT Board on 9th November 2026

New UK SACT Board National Intrathecal and Intraventricular SACT Guidance

Dear colleagues, We are pleased to share the newly published UK SACT Board National Guidance on the Safe Administration of Systemic Anti-Cancer Therapies via the Intrathecal or Intraventricular Routes. This…

Read article
By BOPA Executive Committee on 9th November 2026

BOPA members flying the flag for cancer pharmacy at ESMO 2026

It was fantastic to see BOPA members representing cancer pharmacy at ESMO Congress 2026 in Madrid, which brought together the global cancer community from 23 to 27 October to share…

Read article
By BOPA Executive Committee on 30th October 2026

Publication of Pharmaceutical Technology and Pharmacology of Parenteral Oncology Drugs

We are delighted to recognise the recent publication of Pharmaceutical Technology and Pharmacology of Parenteral Oncology Drugs, a new book bringing together expertise from oncology pharmacy professionals across the world.…

Read article